Skip to main content

Advertisement

Log in

Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases

  • Original Paper
  • Published:
Springer Seminars in Immunopathology Aims and scope Submit manuscript

Abstract

This is a review of the clinical responses and prospectus of new therapies following use of allogeneic hematopoietic stem cell transplantation for the treatment of the following disorders: Hurlers syndrome (MPS 1-H), globoid cell leukodystrophy (GLD; Krabbes disease), adrenoleukodystrophy, metachromatic leukodystrophy, Wolmans disease, I-cell disease (mucolipidosis II; MLS-II), α-mannosidosis, fucosidosis, Niemann-Pick B/A disease, Slys disease (MPS VII), Gauchers disease (Gaucher-II-III), Battens disease, Farbers disease, Sanfilippo syndrome (MPS-III), Hunters disease (MPS-II), Maroteaux-Lamy syndrome (MPS-VI), and aspartylglucosaminuria (AGU). Over 500 patients with lysosomal and peroxisomal metabolic storage diseases due to deficiency of primary enzymes have been treated with hematopoietic stem cell transplantation since the initial patient was treated a quarter of century ago. Normal enzymatic activity has been robust and continuous over these years without the need for any medication. Proof of principle has been reported for multiple positive effects including that of the reconstruction of the central nervous system. Furthermore, the excellent engraftment rate along with significantly diminished graft-vs-host-disease needs to be emphasized. The genetic diseases enumerated above have remarkable differences from those discussed elsewhere in this issue of Seminars in Immunopathology. Each has a greater genetic heterogeneity. Misdiagnosis resulting in delay of treatment and further decline of function and ultimate quality of life occurs almost all the time. Neonatal screening of these diseases will be mandatory to vastly improve outcomes. Plans are being implemented to use dried blood spots on filter paper, as is commonly done for many other genetic diseases. Many new therapies are being adopted which should enhance positivity and acceptance of treatment by hematopoietic stem cell transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aubourg P, Blanche S, Jambaque I, et al (1990) Reversal of early neurological and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med 322:1860

    Google Scholar 

  2. Baker RH, Trautman JC, Zimmerman D (1990) Late juvenile onset Krabbe’s disease. Ophthalmology 97:1176

    Google Scholar 

  3. Bayever E, August CS, Kamani N, et al (1992) Allogeneic bone marrow transplanatation for Nieman-Pick Disease (Type IA). Bone Marrow Transplant 10 (Suppl 1):85

    Google Scholar 

  4. Bezman I, Moser AB, Raymond GV, et al (2001) Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann Neurol 29:512

    Google Scholar 

  5. Biswas S, Levine SM (2002) Substrate-reduction therapy enhances the benefits of bone marrow transplantation in young mice with globoid cell leukodystrophy. Pediatr Res 51:40

    Google Scholar 

  6. Braunlin EA, Hopwood JJ, Krivit W, et al (2001) Coronary artery patency following long-term successful engraftment 14 years after bone marrow transplantation in Hurler (MPS I-H). Am J Cardiol 88:1075

    Google Scholar 

  7. Braunlin EA, Hopwood JJ, Krivit W, et al (2003) Usefulness of bone marrow transplantation in the Hurler syndrome. Am J Cardiol 93:882

    Google Scholar 

  8. Cox TM, Lachmann R, Hollak C, et al (2000) Novel oral treatment of Gaucher’s disease with N-butyldeoxynojiumycin (OCT 918) to decrease substrate biosynthesis. Lancet 355:1401

    Google Scholar 

  9. DeGasperi R, Krivit W, Kolodny EH, et al (1996) Molecular heterogeneity of late-onset form of globoid cell leukodystrophy. Am J Hum Genet 59:1233

    Google Scholar 

  10. De Gasperi R, Raghavan SS, Krivit W, et al (2000) Measurements from normal umbilical cord blood of four lysosomal enzymatic activities: alpha-l-iduronidase (Hurler), galactocerebrosidase (globoid cell leukodsytrophy), arylsulfatase A (metachromatic leukodystrophy). Bone Marrow Transplant 25:541

    Google Scholar 

  11. Ezoe T, Vanier M, Suzuki K, et al (2000) Twitcher mice with only a single active galactosylceramide synthase gene exhibit clearly detectable but therapeutically minor phenotype improvements. J Neurosci Res 59:179

    Google Scholar 

  12. Gasper PW, Thrall MA, Wenger DA, et al 1984) Correction of feline arylsulfatase B deficiency (MPS VI) by bone marrow transplantation. Nature 311:467

    Google Scholar 

  13. Grewal SS, Shapiro EG, Krivit W, et al (2004) Effective treatment of α-mannosidosis by allogeneic stem cell transplantation. J Pediatr 144:569–573

    Google Scholar 

  14. Guffon N, Souillet G, Maire I, et al (1999) Follow-up of nine patients with Hurler syndrome after bone marrow transplantation. J Pediatr 133:119

    Google Scholar 

  15. Guo AC, Petrella JR, Kurtzberg J, et al (2001) Evaluation of white matter anisotropy in Krabbe disease with diffusion tensor MR imaging. Initial experience. Radiology 215:809

    Google Scholar 

  16. Hite S, Peters C, Krivit W (2000) Correction of odontoid dysplasia following bone marrow transplantation and engraftment in Hurler syndrome(MPSI-H). Pediatr Radiol 30:464

    Google Scholar 

  17. Jacobson P, Prak JJ, Defor TE, et al (2001) Oral busulfan pharmacokinetics and engraftment in childen with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 27:855

    Google Scholar 

  18. Keeling KM, Brooks DA, Hopwood JJ (2001) Gentamycin-mediated suppression of Hurler syndrome stop mutations restores a low level of α-l-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum Mol Genet 10:201

    Google Scholar 

  19. Keene CD, Rodrigues, CM, Steer CJ, et al (2002) Taurodesoxycholiic acid, a bile acid, is neuroprotective in a transgeneic animal model of Huntingtons’s disease. Proc Natl Acad Sci USA 99:10671

    Google Scholar 

  20. Krivit W (2002) Stem cell bone marrow transplantation in patients with metabolic storage diseases. Adv Pediatr 49:359

    Google Scholar 

  21. Krivit W (2004) Metachromatic Leukodystrophy. In: Zimran E (ed) Glycolipid storage diseases. Adis International, Oxford 9:91–100

  22. Krivit W, Pierpont ME, Ayaz K, et al (1984) Bone marrow transplantation in the Maroteaux-Lamy syndrome(MPS VI). Biochemical and clinical status 24 months after transplantation. N Engl J Med 311:1606

    Google Scholar 

  23. Krivit W, Freese D, Chan KW, Kulkarni R (1992) Wolman’s disease: a review of treatment with bone marrow transplantation and considerations for the future. Bone Marrow Transplant 10 (Suppl 1):97

    Google Scholar 

  24. Krivit W, Shapiro EG, Peters C, et al (1998) Hematopoietic stem cell transplantation in globoid cell leukodystrophy: N Engl J Med 338:1119

    Google Scholar 

  25. Krivit W, Peters C, Dusenbery K, et al (2000) Wolman disease successfully treated by bone marrow transplantation. Bone Marrow Transplant 26:567

    Google Scholar 

  26. Krivit W, Kurtzberg J, Kolodny EH, et al (2004) Globoid cell leukodystrophy (Krabbe disease): study of normal umbilical cord blood galactocerebrosidase activity and polymorphic mutations. In: Abstracts of American Neurochemicl Socity Meeting, New York, 18 August

  27. Krivit W, Kurtzberg J, et al (2004) Proof of Principle: globoid cell leukodystrophy late-onset: effective therapeutic intervention in disease course by use of hematopoietic stem cell transplantation. In: Abstracts of the 149 Annual Meeting of Pediatric Academic Societies, San Francisco, 2 May 2004

  28. Lachman RH, Platt FM (2001) Substrate reduction therapy for sphingolipid storage disorders. Expert Opin Investig Drugs10:455

    Google Scholar 

  29. Liu Y, Wada R, Kawa H (1999) A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder. J Clin Invest 102:497

    Google Scholar 

  30. Li Y, Brockman K, Scott CR, et al (2004) Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for Krabbe disease. Clin Chem 50:638

    Google Scholar 

  31. Maria BJ, Moser H, Naidu S, et al (2003 ) Leukodystrophies, pathogenesis, diagnosis, strategies, therapies and future directions. J Child Neurol 18:578

    Google Scholar 

  32. Meilke PJ, Brooks DA, Hopwood J (1997) Diagnosis of lysosomal storage disorders: evaluation of lysosome-associated-membrane protein (LAMP-1) as a diagnostic marker. Clin Chem 43:1325

    Google Scholar 

  33. Meilke PJ, Hopwood JJ, Clague AE, et al (1999) Prevalence of lysosomal storage diseases. JAMA 281:249

    Google Scholar 

  34. Moser HW, Loes DJ, Melham ER (2000) X-linked adrenoleukodystrophy: overview and prognosis as a function of age and brain magnetic resonance imaging abnormality. A study involving 372 patients. Neuropediatrics 31:227

    Google Scholar 

  35. Moser HW, Raymond GV, Koehler W, et al (2003) Evaluation of the preventive effect of glyceryl trioleate-trierucate (“Lorenzo’s Oil”) therapy in x-linked adrenoleukodystrophy: results of concurrent trials. Adv Exp Med Biol 544:369

    Google Scholar 

  36. Peters C (2004) Hematopoietic stem cell transplantation for storage diseases. In: Blume KG, Forman SJ, Applebaum FR (eds) Hematopoietic stem cell transplantation, 3rd edn. Blackwell, Oxford, pp 1455–1470

  37. Peters C, Shapiro EG, Krivit W, et al (1998) Hurler: II. Outcome of HLA genotypically HLA-identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. Blood 91:2601

    Google Scholar 

  38. Peters C, Krivit W (2000) Hematopoietic cell transplantation for MPS IIB (Hunter syndrome): an ethical commentary. Bone Marrow Transplant 25:1097

    Google Scholar 

  39. Peters C, Krivit W, et al (2004) Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982–1999. Blood 104:881–888

    Google Scholar 

  40. Richards K, Krivit W, Kurtzberg J, et al (2002) Correction of Krabbe disease with neonatal hematopoietic stem cell transplantation (Neurodevelopmental function and survival). In: Abstracts for the American Society for Blood and Marrow Transplantation, 22–26 February, Orlando, Florida

  41. Rose AG, Braunlin EA, Krivit W (2001) Cardiac disease in Hurler syndrome: an autopsy study of 14 patients including evidence that bone marrow transplantation prevents coronary arterial, myocardial and valvar disease. In: Lewis BA, Halen DA, et al (eds) Advances in Coronary Artery Disease. pp 695–700

  42. Shapiro EG, Lockman L, Krivit W (1991) Bone marrow transplantation as treatment for globoid cell leukodystrophy. In: Desnick RJ (ed) Treatment of genetic diseases. Churchill-Livingstone, New York, pp 222–238

  43. Shapiro EG, Lipton ME, Krivit W (1992) White matter dysfunction and its neuropsychological correlates: a longitudinal study of a case of metachromatic leukodystrophy treated with bone marrow transplantation. J Clin Exp Neuropsychol 14:610

    Google Scholar 

  44. Shapiro EG, Krivit W, Lockman L, et al (2000) Long-term effect of bone marrow transplantation for childhood-onset cerebral X-linked adrenoleukodsytrophy. Lancet 356:713–718

    Google Scholar 

  45. Staba SI, Krivit W, Kurtzberg J, et al (2004) Cord blood transplantation from unrelated donors in patients with Hurler syndrome. N Engl J Med 35:1960–1969

    Google Scholar 

  46. Deleted

  47. Taylor RM, Farrow BRH, Stewart GI (1992) Amelioration of clinical disease following bone marrow transplantation in fucosidase deficient dogs. Am J Med Genet 42:628

    Google Scholar 

  48. Tift CI, Proia RL (2000) Stemming the tide: glycosphingolipid synthesis inhibitors as therapy for storage diseases. Glycobology 10:1249

    Google Scholar 

  49. Turner AT, Hopwood JJ, Brooks DA (2000) Enzyme replacement therapy in mucopolysaccharidosis I. Altered distribution and targeting of α-l-iduoinidase in immunized rats. Mol Genet Metab 69:277

    Google Scholar 

  50. Van Geel BM, Bezman I, Loes DJ, et al (2001) Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. Ann Neurol 49:186

    Google Scholar 

  51. Vermoor J, Ehlert K, Bielacks S, et al (2002) Successful allogeneic stem cell transplantation in infantile ceramidase deficiency (Farber disease) type 2/3. Blood 100:4577

    Google Scholar 

  52. Vinnalongan X, Sanz N, et al (1992) Hypertrophic cardiomyopathy in mucopolysaccharidosis: regression after bone marrow transplantation. Pediatr Cardiol 13:10

    Google Scholar 

  53. Wall DA, Grangre DK, Gaulding P, et al (1998) Bone marrow transplantation for the treatment of α-mannosidosis. J Pediatr 133:282

    Google Scholar 

  54. Sivakumar P, Wraith JE (1999) Bone marrow transplantation in mucopolysaccharidosis Type III A: A comparison of an early treated patient with his untreated sibling. Journal of Inherited Metabolic Disease 22:1849–1850

    Google Scholar 

  55. Yeager AM, Uhai KA, Coles CD (2000) Bone marrow transplantation for infantile ceramidase deficiency (Farber disease). Bone Marrow Transplant 26:357

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to William Krivit.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krivit, W. Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases. Springer Semin Immun 26, 119–132 (2004). https://doi.org/10.1007/s00281-004-0166-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00281-004-0166-2

Keywords

Navigation